Boehringer Ingelheim agreed to invest $10 billion in U.S. operations through 2028 and to participate in the TrumpRx.gov direct‑purchase platform under a White House memorandum aimed at lowering drug costs. The deal includes commitments to expand manufacturing and exempts the company from Section 232 tariff actions. Jean‑Michel Boers, president and CEO of Boehringer Ingelheim USA, framed the agreement as increasing supply‑chain resilience and patient access for chronic disease medicines. The administration described the arrangement as part of a broader effort to secure discounted medicines and domestic capacity. The arrangement highlights a transactional approach from government to secure price concessions and industrial investment; other drugmakers have struck similar deals that mix pricing concessions with manufacturing commitments and policy carve‑outs.